Genmab — November 2019
-
Der er nogle opgørelser over (jeg har ikke lige styr på hvor), hvilket GAK shorter-fondene sidder med. Er der nogen som ligger inde med dette overblik og kan dele. Kunne være interessant at vide hvor mange shortere som brænder inde...
-
Hanken knækkede af. Hvem kommer med superlimen.
-
-
well, vi fik da et nyt intraday ATH ud af det
-
sådan rent teknisk har Genmab vidst ikke rigtigt makket ret gennem tiderne! Historikken mht TA er imod os, de sidste 4-5 år
-
-
-
Is this JNJ-64407564: "A fully humanized immunoglobulin G4 proline, alanine, alanine (IgG4 PAA) based bispecific antibody directed against cluster of differentiation 3 (CD3) receptor complex and G protein coupled receptor family C group 5 member D (GPRC5D), EMEA-002615-PIP01-19, from Janssen-Cilag International N.V., for the treatment of multiple myeloma
-
if i understand correctly, a waiver from the pediatric committee means that you don't have to gather certain data from children , which otherwise would be required in a trial. It is more an administration issue, but it means they are on the case and doing admin work for EMA imo
-
Den 2.5 milestone må da være lige op over nu.....
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind